Aptimmune is a biotechnology company that specializes on developing mucosal vaccines for swine.
Aptimmune's investors include Arsenal Capital Partners, Cultivation Capital, Kemin Industries, The Yield Lab, Illinois Ventures.
Aptimmune is headquartered in St Louis, United States.
Aptimmune is a biotechnology company that specializes on developing mucosal vaccines for swine.
Aptimmune is at the Convertible Note stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Aptimmune — Funding & Investors." VCBacked, January 10, 2022, https://www.vcbacked.co/company/aptimmune. Accessed September 30, 2026.
VCBacked. (2022). Aptimmune — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/aptimmune
{{cite web |title=Aptimmune — Funding & Investors |url=https://www.vcbacked.co/company/aptimmune |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated